Navigation Links
New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study
Date:10/6/2008

wide.
In the U.S., REMICADE is approved for the following indications:

-- Reducing signs and symptoms, inhibiting the progression of structural

damage and improving physical function in patients with moderately to

severely active RA, when administered in combination with methotrexate.

-- Reducing signs and symptoms in patients with active AS.

-- Reducing signs and symptoms and inducing and maintaining clinical

remission in adult and pediatric patients with moderately to severely

active CD who have had an inadequate response to conventional therapy.

-- Reducing the number of draining enterocutaneous and rectovaginal

fistulas and maintaining fistula closure in adult patients with

fistulizing CD.

-- Reducing signs and symptoms, inducing and maintaining clinical

remission and mucosal healing, and eliminating corticosteroid use in

patients with moderately to severely active UC who have had an

inadequate response to conventional therapy.

-- Reducing signs and symptoms of active arthritis, inhibiting the

progression of structural damage and improving physical function in

patients with PsA.

-- Treatment of adult patients with chronic severe plaque PsO who are

candidates for systemic therapy and when other systemic therapies are

medically less appropriate.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

Important Safety Information

<
'/>"/>
SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. More Findings on Gene Involved in Childhood Asthma
2. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
3. VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer
4. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
5. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
6. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
7. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
8. Study Findings Show Infection Control Intervention Helps Keep Kids in School
9. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
10. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
11. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  RESMED INC. (NYSE: RMD ... and fiscal year ended June 30, 2014 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:7/10/2014)...  BC Technical, the largest nationwide, non-OEM provider of ... a leading provider of Siemens Nuclear Medicine and Molecular ... BC Technical as the authorized provider of service and ... BC Technical announced today that the two companies have ... the service and systems provider for MiE,s camera systems. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Oct. 17, 2011 Archimedes Pharma Ltd., and its ... (fentanyl) nasal spray is now available by prescription in ... breakthrough pain in cancer patients 18 years of age ... tolerant to opioid therapy for their underlying persistent cancer ...
... Calif., Oct. 17, 2011 Abaxis, Inc. (NasdaqGS: ABAX), a ... a conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on Tuesday, ... the second quarter of fiscal year 2012 after the market ...
Cached Medicine Technology:Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Most professional football ... return to the game, a new study finds. ... but their rate of return after surgery to fix ... The new study included 60 players who had ... this procedure successfully returned to play, defined as playing ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... the hot flashes that often accompany menopause, new research suggests. ... percent of menopausal women, said Dr. Taraneh Shirazian, an assistant ... Icahn School of Medicine at Mount Sinai Hospital in New ... 10 hot flashes a day, and she added that hot ...
(Date:7/10/2014)... By Dennis Thompson ... -- About six out of 10 adults make use of ... to order in restaurants, according to a new U.S. study. ... study,s lead author, Seung Hee Lee-Kwan, an epidemiologist with the ... of women surveyed said they used menu labeling to help ...
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Knopp Neurosciences Inc. ("Knopp"),announced that Cheryl Fossum Graham, ... president of regulatory and development strategy. (Logo: ... to Knopp 28 years of experience in public ... Food,and Drug Administration and responsibility for global regulatory ...
... ALOKA is announcing today 3 new models of,ProSound Systems ... on,Ultrasound in Obstetrics and Gynecology, 7th to 11th of ... a powerful, friendly and compact,premium ultrasound system, the ProSound ... system worldwide and the ProSound 6,is a new premium ...
... Nancy Pelosi,released the following statement today in recognition ... presented the National Breast,Cancer Coalition,s "Wo(men) Who Get ... "National Breast Cancer Awareness Month is a ... ourselves to advancing prevention, improving,treatments, and funding research ...
... 29, over 850,people in 60 cities across the country ... the Crossfit Fight Gone Bad Challenge to,raise money for ... Cancer,Foundation. Over 4,000 donors supported the cause by contributing ... funds grant from Safeway, the,event raised over $546,000 in ...
... advance in understanding the genetic processes that give flowers, ... lead to a range of benefits, including better understanding ... natural food colourings. The research is highlighted in the ... Sciences Research Council (BBSRC). , The scientists, at the ...
... support services in Los ... Angeles, ... in association with the Will and Jada Smith,Family Foundation hosted the First ... Rey Theatre in Los,Angeles. Actress Jada Pinkett Smith headlined a group of ...
Cached Medicine News:Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2Health News:Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 3Health News:Aloka to Unveil New 'ProSound' Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy 2Health News:Aloka to Unveil New 'ProSound' Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy 3Health News:Crossfit Workout Challenge Raises Over $500,000 in Four Hours for Athletes for a Cure 2Health News:New research into plant colors sheds light on antioxidants 2Health News:Stars Shine on 'Butterflies Over Hollywood' for Lupus Foundation of America 2
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
... has been designed to enhance fixation in ... hole configurations. The objective of the product ... primary modes: Tilt, migration and rotation. The ... initial and long-term fixation. The porous coating ...
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: